Metabolomics in ischaemic stroke, new diagnostic and prognostic biomarkers;La metabolómica en el ictus isquémico, nuevos biomarcadores diagnósticos y pronósticos

Revista de Neurologia

Volumn 57, Issue 1, 2013, Pages 29-36

  Mauri Capdevila, Gerard ^a   Jové, Mariona ^b   Suárez Luis, Idalmis ^a   Portero Otín, Manuel ^b   Purroy, Francisco ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^b UNIVERSITY OF LLEIDA   (Spain)

Author keywords

Biomarkers; Diagnosis; Ischaemic stroke; Metabolites; Metabolomics; Pathophysiology

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BRAIN ISCHEMIA; CELL METABOLISM; EARLY DIAGNOSIS; HUMAN; METABOLITE; METABOLOMICS; PROGNOSIS; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; METABOLISM; PATHOPHYSIOLOGY; RAT; REVIEW; SPRAGUE DAWLEY RAT; CARDIOVASCULAR DISEASES;

ANIMALS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; HUMANS; METABOLOMICS; PROGNOSIS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84879661804     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5701.2013115     Document Type: Article

References (53)

1. Heuschmann PU, Di Carlo A, Bejot Y, Rastenyte D, Ryglewicz D, Sarti C, et al. Incidence of stroke in Europe at the beginning of the 21st century. Stroke 2009; 40: 1557-63.
2. Jung JY, Lee HS, Kang DG, Kim NS, Cha MH, Bang OS, et al. 1H-NMR-based metabolomics study of cerebral infarction. Stroke 2011; 42: 1282-8.
3. Laborde CM, Mourino-Alvarez L, Akerstrom F, Padial LR, Vivanco F, Gil-Dones F, et al. Potential blood biomarkers for stroke. Expert Rev Proteomics 2012; 9: 437-49.
4. Castillo J, Rodriguez I. Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis 2004; 17 (Suppl 1): S7-18.
5. Wong DTH, George K, Wilson J, Manlhiot C, McCrindle BW, Adeli K, et al. Effectiveness of serial increases in amino-terminal pro-B-type natriuretic peptide levels to indicate the need for mechanical circulatory support in children with acute decompensated heart failure. Am J Cardiol 2011; 107: 573-8.
6. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005; 1: 101-8.
7. Bogdanov M, Matson WR, Wang L, Matson T, Saunders- Pullman R, Bressman SS, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008; 131: 389-96.
8. Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 2006; 129: 877-86.
9. Gonzalo H, Brieva L, Tatzber F, Jove M, Cacabelos D, Cassanye A, et al. Lipidome analysis in multiple sclerosis reveals protein lipoxidative damage as a potential pathogenic mechanism. J Neurochem 2012; 123: 622-34.
10. Jiang Z, Sun J, Liang Q, Cai Y, Li S, Huang Y, et al. A metabonomic approach applied to predict patients with cerebral infarction. Talanta 2011; 84: 298-304.
11. Zhang A, Sun H, Wang X. Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl Biochem Biotechnol 2012; 168: 1718-27.
12. Stoop MP, Coulier L, Rosenling T, Shi S, Smolinska M, Buydens L, et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics 2010; 9: 2063-75.
13. Yap IKS, Brown IJ, Chan Q, Wijeyesekera A, Garcia-Perez I, Bictash M, et al. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. J Proteome Res 2010; 9: 6647-54.
14. Sofia M, Maniscalco M, De Laurentiis G, Paris D, Melck D, Motta A. Exploring airway diseases by NMR-based metabonomics: a review of application to exhaled breath condensate. J Biomed Biotechnol 2011; 2011: 403260.
15. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008; 455: 1054-6.
16. Dunn WB, Bailey NJC, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130: 606-25.
17. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181-9.
18. Rochfort S. Metabolomics reviewed: a new 'omics' platform technology for systems biology and implications for natural products research. J Nat Prod 2005; 68: 1813-20.
19. Shah SH, Sun JL, Stevens RD, Bain JR, Muehlbauer MJ, Pieper KS, et al. Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. Am Heart J 2012; 163: 844-50.
20. Shah SH, Kraus WE, Newgard CB. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012; 126: 1110-20.
21. Idle JR, Gonzalez FJ. Metabolomics. Cell Metab 2007; 6: 348-51.
22. Schadt EE, Zhang B, Zhu J. Advances in systems biology are enhancing our understanding of disease and moving us closer to novel disease treatments. Genetica 2009; 136: 259-69.
23. Lenz EM, Wilson ID. Analytical strategies in metabonomics. J Proteome Res 2007; 6: 443-58.
24. Sana TR, Roark JC, Li X, Waddell K, Fischer SM. Molecular formula and METLIN Personal Metabolite Database matching applied to the identification of compounds generated by LC/TOF-MS. J Biomol Tech 2008; 19: 258-66.
25. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006; 34: D354-7.
26. Wishart DS, Jewison T, Guo AC, Wilson M, Knox C, Liu Y, et al. HMDB 3.0 -The Human Metabolome Database in 2013. Nucleic Acids Res 2012; 41: 801-7.
27. Wishart DS. Advances in metabolite identification. Bioanalysis 2011; 3: 1769-82.
28. Gowda GN, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008; 8: 617-33.
29. Goonewardena SN, Prevette LE, Desai A. Metabolomics and atherosclerosis. Curr Atheroscler Rep 2010; 12: 267-72.
30. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 2006; 23: 1075-88.
31. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 2008; 52: 117-23.
32. Wang Z, Tang WHW, Cho L, Brennan DM, Hazen SL. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 2009; 29: 1383-91.
33. Mamatha SN, Nagaraja D, Philip M, Christopher R. Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population. Clin Chim Acta 2011; 412: 139-42.
34. Yoo J, Lee S. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-30.
35. Tang WHW, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol 2009; 53: 2061-7.
36. Sabatine MS, Liu E, Morrow D, Heller E, McCarroll R, Wiegand R, et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005; 112: 3868-75.
37. Serkova NJ, Reisdorph N, Tissot van Patot MC. Metabolic markers of hypoxia: systems biology application in biomedicine. Toxicol Mech Methods 2008; 18: 81-95.
38. Yang M, Wang S, Hao F, Li Y, Tang H, Shi X. NMR analysis of the rat neurochemical changes induced by middle cerebral artery occlusion. Talanta 2012; 88: 136-44.
39. Koizumi S, Yamamoto S, Hayasaka T, Konishi Y, Yamaguchi- Okada M, Goto-Inoue N, et al. Imaging mass spectrometry revealed the production of lyso-phosphatidylcholine in the injured ischemic rat brain. Neuroscience 2010; 168: 219-25.
40. Hattori K, Kajimura M, Hishiki T, Nakanishi T, Kubo A, Nagahata Y, et al. Paradoxical ATP elevation in ischemic penumbra revealed by quantitative imaging mass spectrometry. Antioxid Redox Signal 2010; 13: 1157-67.
41. Saransaari P, Oja SS. Taurine and neural cell damage. Amino Acids 2000; 19: 509-26.
42. Ghandforoush-Sattari M, Mashayekhi SO, Nemati M, Ayromlou H. Changes in plasma concentration of taurine in stroke. Neurosci Lett 2011; 496: 172-5.
43. Naccarato M, Pizzuti D, Petrosino S, Simonetto M, Ferigo L, Grandi FC, et al. Possible anandamide and palmitoylethanolamide involvement in human stroke. Lipids Health Dis 2010; 9: 47.
44. Tuma RF, Steffens S. Targeting the endocannabinoid system to limit myocardial and cerebral ischemic and reperfusion injury. Curr Pharm Biotechnol 2012; 13: 46-58.
45. Kelly PJ, Morrow JD, Ning M, Koroshetz W, Lo EH, Terry E, et al. Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008; 39: 100-4.
46. Pilz S, Tomaschitz A, Meinitzer A, Drechsler C, Ritz E, Krane V, et al. Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography. Stroke 2011; 42: 1132-4.
47. Guercini F, Acciarresi M, Agnelli G, Paciaroni M. Cryptogenic stroke: time to determine aetiology. J Thromb Haemost 2008; 6: 549-54.
48. Mayr M, Yusuf S, Weir G, Chung YL, Mayr U, Yin X, et al. Combined metabolomic and proteomic analysis of human atrial fibrillation. J Am Coll Cardiol 2008; 51: 585-94.
49. Chen X, Liu L, Palacios G, Gao J, Zhang N, Li G, et al. Plasma metabolomics reveals biomarkers of the atherosclerosis. J Sep Sci 2010; 33: 2776-83.
50. Teul J, Rupe FJ, García A, Vaysse J, Malet-Martino M, Martín-Ventura JL, et al. Improving metabolite knowledge in stable atherosclerosis patients by association and correlation of GC-MS and 1H NMR fingerprints. J Proteome Res 2009; 8: 5580-9.
51. Psychogios N, Hau DD, Peng J, Guo AC, Mandal R, Bouatra S, et al. The human serum metabolome. PLoS One 2011; 6: e16957.
52. Kirschenlohr HL, Griffin JL, Clarke SC, Rhydwen R, Grace A, Schofield PM, et al. Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 2006; 12: 705-10.
53. Teul J, García A, Tuñón J, Martín-Ventura JL, Tarín N, Bescós LL, et al. Targeted and non-targeted metabolic time trajectory in plasma of patients after acute coronary syndrome. J Pharm Biomed Anal 2011; 56: 343-51.